• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HAN Lei, ZHANG Xiaomeng, QUAN Xu, LEI Yonghua, QIAN Hai. Research progress of apoptosis signal regulating kinases-1 and its inhibitors in non-alcoholic steatohepatitis[J]. Journal of China Pharmaceutical University, 2019, 50(2): 135-142. DOI: 10.11665/j.issn.1000-5048.20190202
Citation: HAN Lei, ZHANG Xiaomeng, QUAN Xu, LEI Yonghua, QIAN Hai. Research progress of apoptosis signal regulating kinases-1 and its inhibitors in non-alcoholic steatohepatitis[J]. Journal of China Pharmaceutical University, 2019, 50(2): 135-142. DOI: 10.11665/j.issn.1000-5048.20190202
shu

Research progress of apoptosis signal regulating kinases-1 and its inhibitors in non-alcoholic steatohepatitis

More Information
    Graphical Abstract
    • Abstract
  • Non-alcoholic steatohepatitis(NASH)is the most common chronic liver disease. However, the treatment of NASH remains challenging. Apoptosis signal regulating kinases-1(ASK-1)is a member of mitogen-activated protein kinase kinase kinases(MAPKKKs). When the body is stimulated by reactive oxygen species, endoplasmic reticulum stress, calcium influx and extracellular inflammatory signals, c-Jun amino terminal kinases(JNK)and p38 MAPK wiube activated, which then promotes cell proliferation, differentiation, apoptosis and production of inflammatory factors, and causes NASH, fibrosis and other diseases. Therefore, ASK-1 inhibitors can be used to treat NASH. This paper reviews the current treatment methods of NASH, the structure and mechanism of ASK-1, and the research progress of ASK-1 inhibitors in the treatment of NASH in recent years, which aims to explore the guiding significance for the design and development of ASK-1 inhibitors.
    • FullText(HTML)
    • References (42)
  • [1]
    Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64:73-84.
    [2]
    Xu L,Mi YQ.Progress in drug treatment of nonalcoholic fatty liver disease [J].Chin J Clinicians(Electronic Ed)(中华临床医师杂志 电子版),2015,9(20):3666-3670.
    [3]
    Susanne S,Ariel EF.Novel therapeutic strategies targeting ASK1 in NASH[J].Nat Med,2017,23:439-449.
    [4]
    Goldberg D,Ditah IC,Saeian K,et al.Changes in the prevalence of hepatitis C virus infection,nonalcoholic steatohepatitis,and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation[J].Gastroenterology,2017,152:1090-1099.
    [5]
    Yoshio S,Masashi Y.Current and future pharmacological therapies for NAFLD/NASH[J].J Gastroenterol,2018,53(3):362-376.
    [6]
    Yoneda M,Hasegawa T,Sato K.Vitamin E therapy for NAFLD/NASH[J].Nutrition,2015,31:898-899.
    [7]
    Lippman SM,Klein EA,Goodman PJ,et al.Effect of selenium and vitamin E on risk of prostate cancer and other cancers:the selenium and vitamin E cancer prevention trial[J].JAMA,2009,301:39-51.
    [8]
    Schurks M,Glynn RJ,Rist PM,et al.Effects of vitamin E on stroke subtypes:meta-analysis of randomised controlled trials[J].BMJ,2010,4(341):c5702.
    [9]
    Honda Y,Kessoku T,Sumida Y,et al.Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease:an open label,single-arm,multicenter,pilot study[J].BMC Gastroenterol,2017,17:96.
    [10]
    Aithal GP,Thomas JA,Kaye PV,et al.Randomized,placebo controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J].Gastroenterology,2008,135:1176-1184.
    [11]
    Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American association for the study of liver diseases[J].Hepatology,2018,67(1):328-357.
    [12]
    Singh S,Singh PP,Singh AG,et al.Statins are associated with a reduced risk of hepatocellular cancer:a systematic review and meta-analysis[J].Gastroenterology,2013,144:323-332.
    [13]
    Neuschwander-Tetri BA,Loomba R,Sanyal AJ,et al.NASH Clinical Research Network.Farnesoid 9 nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial[J].Lancet,2015,385(9972):956-965.
    [14]
    Miyakawa K, Matsunaga S, Kanou K, et al. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction[J].Nat Commun,2015,6:6945.
    [15]
    Okazaki T,Higuchi M,Takeda K,et al.The ASK family kinases differentially mediate induction of type I interferon and apoptosis during the antiviral response[J].Sci Signal,2015,8(388):ra78.doi: 10.1126/scisignal.aab1883.
    [16]
    Hattori K,Naguro I,Runchel C,et al.The roles of ASK family proteins in stress response and disease[J].Cell Commun Signal,2009,7:9.doi: 10.1186/1478-811X-7-9.
    [17]
    Iriyama T,Takeda K,Nakamura H,et al.ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis[J].EMBO J,2009,28(7):843-853.
    [18]
    Federspiel JD, Codreanu SG, Palubinsky AM, et al. Assembly dynamics and stoichiometry of the apoptosis signal-regulating kinase(ASK)signalosome in response to electrophile stress[J].Mol Cell Proteomics,2016,15(6):1947-1961.
    [19]
    Weijman JF, Kumar A, Jamieson SA, et al. Structural basis of autoregulatory scaffolding by apoptosis signal-regulating kinase 1[J].PNAS,2017,114(11):E2096-E2105.
    [20]
    Hanschmann EM,Godoy JR,Berndt C,et al,Thioredoxins,glutaredoxins,and peroxiredoxins-molecular mechanisms and health significance:from cofactors to antioxidants to redox signaling[J].Antioxid Redox Signal,2013,19(13):1539-1605.
    [21]
    Kosek D,Kylarova S,Psenakova K.Biophysical and structural characterization of the thioredoxinbinding domain of protein kinase ASK1 and its interaction with reduced thioredoxin[J].J Biol Chem,2014,289(35):24463-24474.
    [22]
    Xiang M,Wang PX,Wang A,et al.Targeting hepatic TRAF1-ASK1 signaling to improve inflammation,insulin resistance,and hepatic steatosis[J].J Hepatol,2016,64:1365-1377.
    [23]
    Yu Z,Chen T,Li X,et al.Lys29-linkage of ASK1 by Skp1-Cullin 1-Fbxo21 ubiquitin ligase complex is required for antiviral innate response[J].eLife,2016,5:e14087.
    [24]
    Kawarazaki Y, Ichijo H, Naguro I. Apoptosis signal-regulating kinase 1 as a therapeutic target[J].Expert Opin Ther Targets,2014,18(6):651-664.
    [25]
    Petrvalska O,Kosek D,Kukacka Z,et al.Structural insight into the 14-3-3 protein-dependent inhibition of protein kinase ASK1(apoptosis signal-regulating kinase-1)[J].J Biol Chem,2016,291(39):20753-20765.
    [26]
    Onkar S, Anthony S, Peter C, et al. Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design[J].Protein Sci,2013,22(8):1071-1077.
    [27]
    Frank L,Paul M,Christophe A,et al.Rational approach to highly potent and selective apoptosis signal-regulating kinase 1(ASK1)inhibitors[J].Eur J Med Chem,2018,145:606-621.
    [28]
    Sakauchi C,Wakatsuki H,Ichijo H,et al.Pleiotropic properties of ASK1[J].Biochim Biophys Acta,2017,1861:3030-3038.
    [29]
    Ryoichi H,Teruyuki H,Kohsuke T,et al.Therapeutic targets in the ASK1-dependent stress signaling pathways[J].Proc Jpn Acad,2012,88:434-453.
    [30]
    Kim EK,Choi EJ.MAPK signaling in human diseases:an update[J].Arch Toxicol,2015,89:867-882.
    [31]
    Nishida T,Hattori K,Watanabe K.The regulatory and signaling mechanisms of the ASK family[J].Adv Biol Regul,2017,66:2-22.
    [32]
    Xie L,Wang PX,Zhang P,et al.DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity[J].J Hepatol,2016,65:113-124.
    [33]
    Yamamoto E,Dong Y.F,Kataoka K.et al.Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes,accompanied by apoptosis signal regulating kinase-1 inhibition[J].Hypertension,2008,52:573-580.
    [34]
    Gilead sciences,INC.Apoptosis signal-regulating kinase inhibitor:WO,2013/112741 A1[P].2013-08-01[2019-03-11] .
    [35]
    Karnik S,Charlton M,Li L,et al.Efficacy of an ASK1 inhibitor to reduce fibrosis and steatosis in a murine model of NASH is associated with normalization of lipids,hepatic gene expression,and a reduction in serum biomarkers of inflammation and fibrosis[J].Hepatology,2015,62(Suppl):877A.
    [36]
    Talal AH, Feron-Rigodon M, Madere J, et al. Simtuzumab,an antifibrotic monoclonal antibody against lysyl oxidase-like 2(LOXL2)enzyme,appears safe and well tolerated in patients with liver disease of diverse etiology [J].J Hepatology,2013,58(Suppl 1):S409-S556.
    [37]
    Ikenaga N, Liu SB, Peng ZW, et al. Dual combination therapy directed against lysyl oxidase-like 2(LOXL2)and apoptosis signal-regulating kinase 1(ASK1)potently inhibits fibrosis and portal hypertension in a new mouse model of PSC-like liver disease[J].Hepatology,2015,62(Suppl):881A.
    [38]
    Rohit L,Eric L,Parvez S,et al.The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis:a randomized,phase 2 trial[J].Hepatology,2018,67(2):549-559.
    [39]
    Sunshine Lake Pharma Co.,Ltd.Amide derivative and use thereof in medicine:WO,2018/090869 A1[P].2018-05-24[2019-03-11] .
    [40]
    Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Kinase inhibitor and preparation method therefor and use thereof:WO,2018/149284 A1[P].2018-08-23[2019-03-11] .
    [41]
    Eli lilly and company.Isoquinolin and naphthydrin compouds:WO,2018/160406 A1[P].2018-09-07[2019-03-11] .
    [42]
    Jiangsu Hanson Pharmaceutical Group Co.,Ltd.Amide derivative inhibitor and preparation method and application thereof:WO,2018/157856 A1[P].2018-09-07[2019-03-11] .
    • Related Articles

  • Related Articles

    [1]ZHANG Yuting, WANG Anhui, YANG Jinni, LIN Jiachun, TIAN Yuan, DONG Haijuan, ZHANG Zunjian, SONG Rui. Mechanisms of cholesterol metabolism imbalance in a PA-induced non-alcoholic fatty liver disease cell model[J]. Journal of China Pharmaceutical University, 2023, 54(4): 490-500. DOI: 10.11665/j.issn.1000-5048.2023032401
    [2]CHEN Xin, YANG Qian, YOU Qidong, GUO Xiaoke. Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
    [3]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [4]TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101
    [5]LU Lu, GUO Qinglong, ZHAO Li. Advances of Src kinase family and paclitaxel resistance[J]. Journal of China Pharmaceutical University, 2017, 48(4): 377-383. DOI: 10.11665/j.issn.1000-5048.20170401
    [6]CHENG Yulan, MEN Jinxia, ZHOU Jinpei, ZHANG Huibin. Advances in indoleamine 2, 3-dioxygenase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(3): 361-370. DOI: 10.11665/j.issn.1000-5048.20170318
    [7]YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
    [8]YAO Aihong, CHANG Yujie, JIANG Cheng, SUN Haiying. Research progress of Polo-like kinase 1 inhibitors targeting Polo-box domain[J]. Journal of China Pharmaceutical University, 2016, 47(1): 1-8. DOI: 10.11665/j.issn.1000-5048.20160101
    [9]YIN Lei, WANG Ying, CHEN Song, GAO Xiangdong. Advances of glucagon-like peptide-1 receptor agonists in the treatment of nervous system diseases[J]. Journal of China Pharmaceutical University, 2014, 45(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20140401
    [10]KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

  • Cited by

    Periodical cited type(2)

    1. 汪云，崔桅. 非酒精性脂肪性肝炎在研新药的现状及进展. 中国处方药. 2023(08): 190-193 .
    2. 汪姝婷，唐金城，李颖，冯江超. ASK1在肾脏相关疾病中的研究进展. 医学综述. 2021(02): 269-274+279 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (1132) PDF downloads (1530) Cited by(4)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：300509

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return